What did @nattyplusprotocol actually say?
The creator argued that MK-677's effectiveness depends heavily on your baseline growth hormone levels and your age. Specifically, they claimed that "MK is expected to proportionally increase GH more the lower your baseline GH" and that a 19-year-old with already-high GH might only see a 50% increase versus someone with a lower baseline potentially doubling their levels. They also touched on IGF-1 peaking around age 16, the possibility of height effects in still-developing teens, and the idea that long-term supraphysiological IGF-1 might actually be more harmful for older adults than younger ones due to insulin resistance and aging-related illness risk.
The video is dense and covers a lot of ground quickly. The creator is clearly trying to be balanced, acknowledging trade-offs rather than simply hyping MK-677. That's worth noting before we dig into whether the underlying claims hold up.
Does the science back this up?
Partially, yes. The core mechanic they describe, that secretagogues like MK-677 work by stimulating pituitary output and are therefore subject to ceiling effects, is well-supported. But some of the specific numbers and the framing around IGF-1 decline as a protective mechanism need more nuance.
MK-677 (ibutamoren) works as a ghrelin receptor agonist, stimulating the pituitary to release GH. The pituitary ceiling argument has real grounding: Nass et al. (2008, Annals of Internal Medicine) showed MK-677 increased IGF-1 levels in older adults with low baseline GH significantly more than in those with higher baseline levels, consistent with what the creator describes. On the IGF-1 aging trajectory, Bidlingmaier et al. (2014, European Journal of Endocrinology) confirmed IGF-1 peaks in mid-adolescence and declines through adulthood. The creator's estimate of a peak around age 16 is directionally accurate, though there's individual variation. Where things get shakier is the claim about supraphysiological IGF-1 being "more detrimental" for older people, which is an inference built on epidemiological data, not direct trial evidence.
What did they get wrong (or right)?
They got the pituitary ceiling concept mostly right. They got the IGF-1 developmental timeline roughly right. Where the video is weakest is in presenting the "protective mechanism" framing of age-related IGF-1 decline as settled science, when it is still actively debated.
The creator says "there's probably reason IGF-1 declines with age" and frames it as potentially protective. This is a real hypothesis, supported partly by longevity research, including work by Laron (2008, Nature Reviews Endocrinology) showing that IGF-1 deficiency in certain populations correlates with reduced cancer rates. But conflating natural decline with a programmed protective mechanism is a leap. Observational data on IGF-1 and cancer risk is correlational. The creator also says increasing GH in a developing 19-year-old by "50 to 100%" over three years would only "rarely" affect adult height in a salient way. That's a reasonable hedged position, but it's stated without any supporting data, and the reality is we simply don't have good controlled trial data on MK-677 in adolescents specifically. That gap should have been named explicitly.
What should you actually know?
The baseline-dependency argument has legitimate pharmacological support, but the numbers the creator cites, 50% versus 200-400% increases, are not sourced, and the specific figures should not be treated as established benchmarks.
Here's what the evidence actually says: MK-677 does raise IGF-1 measurably in adults. Thorner et al. (1997, Journal of Clinical Endocrinology and Metabolism) found dose-dependent IGF-1 increases in healthy older subjects. The response does vary by baseline, consistent with the creator's claim. But predicting whether any individual will see a 50% or 100% increase based on age alone is not something current research supports with precision. On the safety side, MK-677 carries real concerns at any age: increased fasting glucose, edema, and potential effects on insulin sensitivity documented in multiple trials, including Murphy et al. (1998, European Journal of Endocrinology). The creator briefly gestures at insulin resistance risk but does not give it the weight it deserves. Anyone using MK-677, regardless of age, should be under medical supervision with regular metabolic monitoring. This is not a supplement with a clean long-term safety profile in humans.